leisure time -WSS

leisure time

author：Wikipedia 2025-09-30 18:17:07 - browse：7737

Adam's take main illustration — Molly Ferguson/STAT

This week, a preview of the TUDCA study in ALS and thoughts on how it might impact Amylyx Pharmaceuticals. Also, I chatted with CRISPR Therapeutics CEO Sam Kulkarni about its new investor. Read to the end for some burning questions, random thoughts.

The next ALS data readout — overdue but important

A European academic consortium is expected to announce results soon from a clinical trial investigating the use of a widely available nutritional supplement called tauroursodeoxycholic acid, or TUDCA, in people living with ALS. The outcome of the TUDCA-ALS study could have implications for Amylyx Pharmaceuticals, because TUDCA is one of the two main ingredients in Relyvrio, the company’s approved drug for ALS.

In a recent interview at Amylyx’s Kendall Square headquarters, co-CEOs Justin Klee and Josh Cohen mostly downplayed the suggestion that results from the randomized, placebo-controlled TUDCA study might affect Relyvrio negatively, or even positively.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Obamacare plans could cover weight loss drugs

knowledge

WSS

Why failed clinical trials don’t always spell doom for a new drug

Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

Surprise medical billing ban raises prices elsewhere

Friends ask where James Watson's attitudes about race came from

Measles policy set amid Florida outbreak alarms vaccine proponents

Flagship Pioneering startup Sonata Therapeutics lays off 21

leisure time

leisure time

The next ALS data readout — overdue but important

hotspot

DIEP, the 'gold standard' of breast reconstruction, is under threat

Secretariat’s lessons for human medicine

United colonoscopy coverage change 'may cost lives,' doctors say

Q&A: Figuring out how songbirds sing may lead to better understanding of how humans learn

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Researchers tackle phage therapy hurdles for wider adoption

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

NIH trials fail to test meaningful long Covid therapies, experts say

After affirmative action ruling, medical educators look to 'holistic review'

Methadone doses haven’t kept up in the age of fentanyl

focus

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

The best solution to the drug shortages problem

Wegovy trial has doctors encouraged over new possibilities

Naloxone nonprofit donates 200,000 doses after FDA approval

Weight loss drugs aren’t covered by Obamacare. That may change

Weight loss drugs aren’t covered by Obamacare. That may change

hotspot

knowledge

knowledge

entertainment